Table 1 Baseline clinical characteristics of the study population
|  | Total population, n = 2419 | Without event, n = 1965 | With event, n = 454 | P |
|---|---|---|---|---|
Age, years | 60.08 ± 8.97 | 59.60 ± 8.72 | 62.16 ± 9.70 | <  0.001 |
Male, n (%) | 1737 (71.8) | 1422 (72.4) | 315 (69.4) | 0.203 |
BMI, kg/m2 | 26.21 ± 3.45 | 26.13 ± 3.40 | 26.55 ± 3.61 | 0.019 |
Heart rate, bpm | 69.77 ± 10.15 | 69.44 ± 10.00 | 71.17 ± 10.69 | 0.002 |
SBP, mmHg | 130.30 ± 16.52 | 129.80 ± 15.99 | 132.44 ± 18.50 | 0.005 |
DBP, mmHg | 77.05 ± 9.90 | 77.00 ± 9.68 | 77.25 ± 10.80 | 0.661 |
Smoking, n (%) | 1381 (57.1) | 1127 (57.4) | 254 (55.9) | 0.585 |
Drinking, n (%) | 562 (23.2) | 468 (23.8) | 94 (20.7) | 0.157 |
Family history of CAD, n (%) | 254 (10.5) | 203 (10.3) | 51 (11.2) | 0.572 |
Medical history, n (%) | ||||
 Hypertension | 1511 (62.5) | 1210 (61.6) | 301 (66.3) | 0.061 |
 Prior MI | 527 (21.8) | 348 (17.7) | 179 (39.4) | <  0.001 |
 Prior PCI | 414 (17.1) | 280 (14.2) | 134 (29.5) | <  0.001 |
 Prior CABG | 55 (2.3) | 23 (1.2) | 32 (7.0) | <  0.001 |
 Prior stroke | 281 (11.6) | 204 (10.4) | 77 (17.0) | <  0.001 |
 Prior PAD | 84 (3.5) | 63 (3.2) | 21 (4.6) | 0.137 |
Glycometabolic status | ||||
 Non-diabetes | 926 (38.3) | 829 (42.2) | 97 (21.4) | <  0.001 |
 Pre-diabetes | 645 (26.7) | 531 (27.0) | 114 (25.1) | 0.406 |
 Diabetes | 848 (35.1) | 605 (30.8) | 243 (53.5) | <  0.001 |
Laboratory results | ||||
 TGs, mmol/L | 1.84 ± 1.32 | 1.69 ± 1.05 | 2.47 ± 2.00 | <  0.001 |
 TC, mmol/L | 4.17 ± 1.06 | 4.14 ± 1.05 | 4.33 ± 1.07 | 0.001 |
 LDL-C, mmol/L | 2.50 ± 0.88 | 2.50 ± 0.89 | 2.50 ± 0.85 | 0.962 |
 HDL-C, mmol/L | 0.98 ± 0.23 | 0.99 ± 0.24 | 0.92 ± 0.21 | <  0.001 |
 Estimated RLP-C, mmol/L | 0.69 ± 0.42 | 0.65 ± 0.35 | 0.90 ± 0.61 | <  0.001 |
 hs-CRP, mg/L | 1.29 (0.58, 3.31) | 1.22 (0.53, 3.06) | 1.87 (0.77, 4.29) | <  0.001 |
 Creatinine, μmol/L | 76.00 ± 16.95 | 75.68 ± 16.49 | 77.42 ± 18.76 | 0.048 |
 eGFR, ml/(min*1.73m2) | 93.49 ± 20.36 | 94.09 ± 20.11 | 90.91 ± 21.22 | 0.003 |
 Uric acid, μmol/L | 346.22 ± 82.64 | 346.45 ± 81.45 | 345.21 ± 87.69 | 0.774 |
 FBG, mmol/L | 6.20 ± 1.94 | 6.01 ± 1.71 | 7.03 ± 2.57 | <  0.001 |
 HbA1c, % | 5.90 (5.50, 6.60) | 5.80 (5.50, 6.40) | 6.40 (5.80, 8.00) | <  0.001 |
 LVEF, % | 65.00 (60.00, 68.00) | 65.00 (61.00, 69.00) | 63.00 (57.00, 67.00) | <  0.001 |
Initial diagnosis, n (%) | Â | Â | Â | 0.001 |
 UA | 2018 (83.4) | 1662 (84.6) | 356 (78.4) |  |
 NSTEMI | 401 (16.6) | 303 (15.4) | 98 (21.6) |  |
Medical treatment, n (%) | ||||
 ACEI | 734 (30.3) | 577 (29.4) | 157 (34.6) | 0.029 |
 ARB | 948 (39.2) | 753 (38.3) | 195 (43.0) | 0.068 |
 Aspirin | 2417 (99.9) | 1963 (99.9) | 454 (100.0) | 0.496 |
 Clopidogrel | 2415 (99.8) | 1963 (99.9) | 452 (99.6) | 0.109 |
 β-Blocker | 2199 (90.9) | 1780 (90.6) | 419 (92.3) | 0.255 |
 Statins | 2366 (97.8) | 1922 (97.8) | 444 (97.8) | 0.985 |
 Oral hypoglycemic agents | 437 (18.1) | 314 (16.0) | 123 (27.1) | <  0.001 |
 Insulin | 232 (9.6) | 154 (7.8) | 78 (17.2) | <  0.001 |
Angiographic data, n (%) | ||||
 Left main disease | 110 (4.5) | 64 (3.3) | 46 (10.1) | <  0.001 |
 Multi-vessel disease | 1631 (67.4) | 1225 (62.3) | 406 (89.4) | <  0.001 |
 Chronic total occlusion | 345 (14.3) | 202 (10.3) | 143 (31.5) | <  0.001 |
 Diffuse lesion | 605 (25.0) | 431 (21.9) | 174 (38.3) | <  0.001 |
 Bifurcation lesion | 492 (20.3) | 368 (18.7) | 124 (27.3) | <  0.001 |
Number of stents | 1.96 ± 1.29 | 1.87 ± 1.14 | 2.33 ± 1.76 | <  0.001 |